On the other hand, we have not detected any regulatory effects of PRUNE2/PCA3 in late genetic events such as prostate cancer progressing to biochemical recurrence, which includes the development of local tumor recurrence and/or the development of metastatic disease. Here, PCA3 is linked to prostate carcinoma.